Sunak's first budget tackles pharma R&D as well as coronavir...

In his first budget as UK chancellor, Rishi Sunak’s main focus was to prepare the country for the impact of coronavirus – but there were other pharma-friendly measures in there too.

Future proofing the UK’s research ecosystem in the face of g...

The UK is a powerhouse of clinical research but maintaining that leading position – and all the benefits that come with it – in the face of global change requires adaptation.

ABPI looks internally for new CEO, naming Richard Torbett

ABPI’s blueprint to build a pharma powerhouse in uncertain p...

The UK is in the grips of election fever, but whoever takes the reins on 13 December will need to “build a thriving environment for medicines discovery” if they want to improve health outco

Sharing success to unlock the “triple win” of joint working

The fortunes of the NHS and the UK’s life sciences industry are intertwined, with each sector’s success or failure heavily dependent on the other.

Making patient involvement meaningful

True public and patient involvement in research needs to be more than just a box ticking exercise – it needs to be meaningful.